The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
Year: 2013
Type: review
Abstract: BACKGROUND: Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated the influence of different dosing schedules on DP's clinical efficacy. METHODS AND FINDINGS: A systematic search of the literature was conducted to identify all studies published between 1960 and February 2013, in which patients were enrolled and treated with DP. Principal investigators were approached and invited to share individual patient data with the WorldWide Antimalarial Resistance Network (WWARN). Data were pooled using a standardised methodology. Univariable and multivariable risk factors for parasite recrudescence were identified using a Cox's regression model with shared frailty across the study sites. Twenty-four published and two unpublished studies (n = 7,072 patients) were included in the analysis. After correcting for reinfection by parasite genotyping, Kaplan-Meier survival estimates were 97.7% (95% CI 97.3%-98.1%) at day 42 and 97.2% (95% CI 96.7%-97.7%) at day 63. Overall 28.6% (979/3,429) of children aged 1 to 5 years received a total dose of piperaquine below 48 mg/kg (the lower limit recommended by WHO); this risk was 2.3-2.9-fold greater compared to that in the other age groups and was associated with reduced efficacy at day 63 (94.4% [95% CI 92.6%-96.2%], p<0.001). After adjusting for confounding factors, the mg/kg dose of piperaquine was found to be a significant predictor for recrudescence, the risk increasing by 13% (95% CI 5.0%-21%) for every 5 mg/kg decrease in dose; p = 0.002. In a multivariable model increasing the target minimum total dose of piperaquine in children aged 1 to 5 years old from 48 mg/kg to 59 mg/kg would halve the risk of treatment failure and cure at least 95% of patients; such an increment was not associated with gastrointestinal toxicity in the ten studies in which this could be assessed. CONCLUSIONS: DP demonstrates excellent efficacy in a wide range of transmission settings; however, treatment failure is associated with a lower dose of piperaquine, particularly in young children, suggesting potential for further dose optimisation.
Source: PLoS Medicine
Author: The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group
Institution: Liverpool School of Tropical Medicine
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,460
Funders: Bill and Melinda Gates Foundation, World Health Organization, University of Washington, Johns Hopkins University, Wellcome Trust, Menzies School of Health Research, Instituut voor Tropische Geneeskunde, University of Oxford, Charles Darwin University, Universiteit van Amsterdam, Radboud Universiteit, Mahidol University, Medicines for Malaria Venture, University of Cape Town, Directorate for Biological Sciences, Medical Research Council, Faculty of Tropical Medicine, Mahidol University
Awards: Defining the population at risk and burden of disease of Plasmodium vivax malaria., Thailand Major Overseas Programme Core Grant Renewal 2010 to 2015., Improving the treatment of malaria., Optimising antimalarial combination therapies in an area coendemic for vivax and falciparum malaria., The changing endemicity and disease burden of Plasmodium falciparum in Africa since 2000
OpenAlex ID: W1537278034
